Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

NCT06055465 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Sacituzumab Govitecan
DRUG: Pembrolizumab

Sponsor

Chinese University of Hong Kong